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Abstract 
Purpose: [18F]-fluorodeoxyglucose-positron emission tomography (FDG-PET) images are usually 
quantitatively analyzed in "whole-tumor" volumes of interest. Also parameters determined with 
dynamic PET acquisitions, such as the Patlak glucose metabolic rate (MRglc) and pharmacokinetic 
rate constants of 2-tissue compartment modeling are most often derived per lesion. We propose 
segmentation of tumors to determine tumor heterogeneity, potentially useful for dose-painting in 
radiotherapy and elucidating mechanisms of FDG uptake.  
Methods and Materials: In 41 patients with 104 lesions dynamic FDG PET was performed. On MRglc 
images, tumors were segmented in quartiles of background subtracted maximum MRglc (0 – 25%, 
25 – 50%, 50 – 75% and 75 – 100%). Pharmacokinetic analysis was performed using an irreversible 
two-tissue compartment model in the three segments with highest MRglc to determine the rate 
constants of FDG-metabolism.  
Results: From the highest to the lowest quartile, significant decreases of uptake (K1), washout (k2) 
and phosphorylation (k3) rate constants were seen with significant increases in tissue blood volume 
fraction (Vb).  
Conclusions: Tumor-regions with highest MRglc are characterized by high cellular uptake and 
phosphorylation rate constants with relatively low blood volume fractions. In regions with less 
metabolic activity, the blood volume fraction increases and cellular uptake, washout and 
phosphorylation rate constants decrease. These results support the hypothesis that regional tumor 
glucose phosphorylation rate is not dependent on the transport of nutrients (i.e., FDG) to the tumor. 
 
Keywords 
Fluorodeoxyglucose F18 – Positron-Emission Tomography – Pharmacokinetics – 
Tissue Distribution – Patlak analysis 
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Introduction 
Positron emission tomography (PET) is a molecular imaging technique to quantitatively assess 
various tissue properties with an appropriate radiotracer such as [18F]-fluoromisonidazole (FMISO) for 
hypoxia [1] or [18F]-fluorothymidine (FLT) for proliferation [2]. However, [18F]-fluorodeoxyglucose 
(FDG), which visualizes glucose metabolic processes in tissues, remains the most commonly used 
radiotracer with PET. FDG-PET has obtained a clear role in tumor staging [3] and is used to assess 
therapy response and predict outcome [4]. In most cases the standardized uptake value (SUV) is 
used to quantify whole-tumor FDG-uptake. Most tumors however, display heterogeneous uptake in 
FDG-PET images, which may reflect different biologic behavior in the different regions within these 
lesion. Identifying this metabolic heterogeneity would not only be useful for understanding tumor 
biology, but might be of prognostic significance or of use for radiotherapy planning and dose painting 
by intensity-modulated radiation therapy (IMRT) as well [5]. 
To examine processes underlying the uptake of FDG in a tumor, sophisticated quantification 
methods such as determination of pharmacokinetic rate constants of 2-tissue compartment models 
can be used [6;7], requiring dynamic PET images. With these pharmacokinetic analyses, the 
properties of the FDG metabolism can be elucidated. Delivery of FDG in and out the cell corresponds 
to the rate constants K1 and k2, respectively. Once intracellular, phosphorylation of FDG is 
represented by k3, dephosphorylation by k4, and Vb finally, indicates the fraction of blood within the 
volume of interest (VOI). The 2-tissue compartment model of FDG metabolism is shown in figure 1. 
Pharmacokinetic rate constants, and other model-based parameters are usually derived in a VOI, 
mostly representing the whole tumor. These parameters therefore, correspond to averaged values of 
tumor glucose metabolic activity. To assess intratumoral heterogeneity, the parameters could be 
obtained for every individual voxel within the tumor (voxel-wise modeling). The time-activity curves for 
single voxels, however, are relatively noisy. This prevents accurate determination of tumor 
parameters using non-linear least squares (NLLS) methods [8]. Moreover, tumor movement (e.g., as 
a result of breathing) has a relatively large influence in these small volumes as in this case each voxel 
does not necessarily represent a single volume of tissue. 
As a trade-off, less detailed parameters (such as the metabolic rate of glucose (MRglc)) can be 
used, for which voxel-wise quantification is feasible, since they can be based on linearization methods 
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which are far less sensitive to noise (e.g., using the Patlak method [9]). Another method to overcome 
high noise levels is to decrease spatial image resolution by reconstruction at smaller matrix sizes. 
Post-reconstruction smoothing could also be used to increase signal-to-noise ratios at the cost of 
spatial resolution.  
Similarly, higher signal-to-noise ratios can be obtained by tumor segmentation and taking the 
mean value in each segment, which could be used to determine tumor regional variation in 2-tissue 
compartment model rate constants of FDG metabolism (K1-k4) and blood volume fraction (Vb). 
We applied the latter method and segmented the tumors based on the MRglc images, taking 
advantage of the higher tumor-to-background ratio as compared to standard uptake images [10]. 
Furthermore, we wanted to verify our hypothesis that tumor regions with the highest MRglc are 
characterized by high FDG extraction and phosphorylation rates. 
 
Patients & methods 
1. Patient population & data acquisition procedure 
From an existing database of dynamic FDG-PET scans of oncological patients acquired on a 
Siemens ECAT EXACT47 (Siemens Healthcare), 41 patients with 104 tumors of different origin 
(table 1) were selected [11; 12]. Selection criteria were: previously untreated patients in whom a fully 
arterially sampled input function is available. The study was approved by the Institutional Review 
Board of the Radboud University Nijmegen Medical Centre and written informed consent was 
obtained from each patient. Details of the study have been described before with the only difference 
that the present images were reconstructed in 128 × 128 × 47 matrices using 2D ordered subsets 
expectation maximization (OSEM2D) with 4 iterations and 16 subsets and a 5 mm 3-dimensional (3D) 
Gaussian filter. In brief, fasted patients were injected with FDG by an automated standardized 
infusion protocol. Immediately thereafter, 17 arterial blood samples were taken at set time points from 
which plasma was obtained to provide a sampled arterial plasma time activity concentration curve 
(Cplasma(t)). Simultaneously, a dynamic PET-acquisition consisting of 16 time-frames of variable 
duration was obtained to provide the tissue time activity curve). Voxel volumes in the reconstructed 
images were 39.75 mm3 (transaxial voxel size 3.432 × 3.432 mm, axial voxel size 3.375 mm). 
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2. Data analysis 
Data analysis was performed using Inveon Research Workplace (IRW version 2.2, Siemens 
Healthcare). First, voxel-wise Patlak linear regression [9] of acquired data 10 – 50 min post injection 
(the last 5 time-frames) was used to obtain the influx constant (Ki) of each voxel. The slope of the 
Patlak plot equals Ki, and MRglc was calculated by multiplication with the measured venous plasma 
glucose concentration, thereby assuming a lumped constant (LC) of 1, see equation 1. The real value 
of LC is time and tissue dependent and therefore unknown [13]. 
32
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Since pharmacokinetic analysis of dynamic data is sensitive to time-delay (td, i.e., the difference 
in time of arrival of the FDG-bolus in the tumor and in the sampled artery), manual time-offset 
synchronization of Cplasma(t) and Ctumor(t) of VOItumor was performed by visually shifting the ascending 
limbs of both curves until they overlapped. 
On images of MRglc, one representative background VOI (VOIBG) and three tumor VOIs were 
determined per lesion, defined by increasing levels of background-corrected MRglc (VOIlow, VOImedium 
and VOIhigh, summing up to VOItumor; table 2). The quartile with lowest metabolic rate was not 
included, as the edges of the metabolic volume may contain non-tumor tissues and the noise levels in 
this segment is higher due to a lower FDG uptake. We did not attempt any partial-volume correction 
strategies. VOIBG was defined as an ellipsoidal volume of at least the size of the corresponding tumor 
and placed in a representative volume of tissue with normal FDG-uptake (e.g., contralateral lung in 
case of a lung metastasis). 
IRW uses the iterative Levenberg-Marquardt algorithm for NLLS curve fitting, minimizing the 
weighted least squares deviation [14] to obtain all rate constants and Vb simultaneously, in each 
tumor VOI separately. The weighting function was chosen as the square root of the frame duration 
divided by the measured non-decay-corrected activity concentration in each time frame (i.e., Poisson 
weighting). For initialization of the NLLS algorithm, multiple (=99), randomly selected starting 
parameters within a defined range (0.0 – 2.0 for the rate constants, 0.0 – 1.0 for Vb) were used.  
Data from the literature suggest that the rate of dephosphorylation of FDG by glucose-6-
phosphatase activity (k4 in the Phelps 4K [7]) is very low in mammalian tissues, except in liver tissue 
[15]. Moreover, from simulation studies it has been warned that a k4 might result from tissue 
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heterogeneity rather than real dephosphorylation [16]. All pharmacokinetic analyses were performed 
using the Sokoloff 3K (K1-k3) model [6], as it showed a better fit than the Phelps 4K (K1-k4) model [7] 
in a majority of lesions (data on file).  
The resulting values for each parameter were classified as being biologically plausible or not. 
Values within 3 standard deviations (99.7% confidence interval) of the mean described elsewhere 
[17; 18] were considered biologically plausible by definition. This criterion was set to label unrealistic 
tumor parameter values, which could be the result of the instability of the nonlinear optimization of 
extremely noisy time-activity concentration curves. For K1 this meant the interval 0 – 1.049 mL·g-1·min-
1, for k2 0 – 1.455 min-1, for k3 0 – 0.511 min-1 and for Vb 0.001 – 0.335. The subgroup of lesions 
considered having biologically plausible results was analyzed separately, to validate that the 
conclusions drawn based on the whole group were not due to (implausible) outliers. Next, in order to 
evaluate the influence of blurring caused by the partial-volume effect and motion, the subgroup of 
lesions with a volume of at least 14.1 cm3 were analyzed, as this volume represents a lesion with a 
spherical diameter of ~3 cm, which is 5 times the resolution of the scanner (~0.6 cm full width at half 
maximum). 
Finally, these parameters were interpreted in view of their reliability (relative standard error) and 
mutual independence (correlation matrix).  
 
3. Statistical analysis 
(Loge)-normally distributed variables are described by mean and 95%-confidence interval (95%-
CI: mean ± 1.96 × standard deviation). Variables not obeying the (loge)-normal distribution are 
described by median and interquartile range (IQR). For normally distributed values the (paired) t-test 
and the squared Pearson’s Product-Moment Correlation Coefficient (R2) were used to compare 
means or express correlation. In case of non-normality, Spearman’s ρ was used. Correlation was 
qualified based on R2: very high (R2 ≥ 0.9), high (0.7 < R2 < 0.9), intermediate (0.5 < R2 < 0.7) or low 
(R2 <0.5). 
Comparison of multiple groups was performed by non-parametric analysis of variance 
(Friedman’s ANOVA). To correct for multiple comparisons, a post-hoc analysis with Wilcoxon signed 
rank test was conducted with a Dunn’s (or Bonferroni’s) correction. 
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Relations between tumor parameters on the one hand and biological plausibility on the other 
hand were determined using univariable logistic regression. The following continuous variables were 
candidate predictors: volume, Ki, MRglc and SUV of the smallest VOI (segment). Their discriminative 
ability was evaluated by determination of the area under the receiver operating characteristics curves 
(AUC). Difference between the AUC and 0.500 (i.e., AUC for an indiscriminative test) was assessed 
by asymptotic distribution assumption for significance. All statistical analyses were performed using 
SPSS version 16.0.2. The cut-off point for statistical significance was set at 0.05. 
 
Results 
Median lesion volume based on VOItumor was 11.3 cm3 (corresponding to 283.5 voxels), ranging 
from 1.7 to 504 cm3 (42 to 12668 voxels). VOI characteristics of tumor segments are displayed in 
table 3.  
Correlation of the VOItumor parameters showed significant but weak correlation between MRglc 
and K1 (ρ: 0.286, p=0.003), MRglc and k3 (ρ: 0.488, p < 0.001) but not between MRglc and k2 (ρ: -0.088, 
p = 0.372) and MRglc and Vb (ρ: 0.189, p = 0.055). There was also no significant correlation between 
k3 and Vb (ρ: 0.045, p = 0.652). The subgroup of NSCLC showed similar results, as summarized in 
table 4. 
An example of lesion segmentation with corresponding time-activity concentration curves is 
displayed in figure 2. As demonstrated in figure 3, a clear trend in reduction of K1, k2, k3 and increase 
in Vb was observed from VOIhigh toward VOIlow, which was significant for all four investigated 
parameters. The within-group differences were significant between all segments, except for VOIhigh 
versus VOImedium for both K1 and k2. These trends were seen in significantly more than the expected 
25% (if divided equally between the 4 possibilities) of the analyzed lesions: 42% (95%-CI: 33 – 52%) 
for K1, 40% (95%-CI: 31 – 50%) for k2, 79% (95%-CI: 70 – 86%) for k3 and 93% (95%-CI: 87 – 97%) 
for Vb. Similar trends are observed when NSCLC and CRC lesions are considered separately. Forty 
lesions had a volume larger than 14.1 cm3. In this subgroup, the trends were observed in a higher 
percentage of the lesions, as displayed in table 5. 
In 90% of the lesions all four VOItumor parameters were considered biologically plausible. In the 
10 lesions with one or more implausible parameters, K1 was not within the defined plausible range in 
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20%, k2 in 70%, k3 in 40% and Vb in 50% of these lesions. Multivariable logistic regression showed 
only Ki to be independently related to plausibility.  
When looking at the four parameters in the segments VOIhigh, VOImedium and VOIlow separately, in 
45 lesions (43% of the analyzed tumors) all 12 values were within the range of biologic plausibility. In 
the other 59 lesions (57%) with at least one or more resulting implausible parameters in one or more 
VOIs, K1 was not within the plausible range in 15%, k2 in 81%, k3 in 34% and Vb in 61% of these 
lesion. Only the smallest Ki was related to biologically plausible results, which had moderate 
discriminative ability (AUC 0.680, 95%-CI: 0.578 – 0.783). 
When looking only at the 45 lesions with all 12 values within the defined range of biological 
plausibility we saw similar trends between VOIhigh – VOIlow for K1, k3 and Vb. However this did not 
reach statistical significance for k2 (Friedman = 2.80, p = 0.257, downslope trend for VOIhigh – VOIlow in 
33%), see table 5. 
For the 312 NLLS operations (3 tumor segment VOIs in each of the 104 lesions), 10% of K1, 10% 
of k2, 12% of k3 and 20% of Vb showed relative standard errors larger than 5%. In the 104 (larger VOI) 
whole-tumor parameters this was only the case in 4%, 4%, 5% and 5% respectively. Correlation 
matrices of the 312 parameters, showed very high mutual dependence between K1 and k2 (median R: 
0.96, IQR: 0.96 – 0.97), intermediate mutual dependence between K1 and Vb (median R: -0.73, IQR: 
-0.83 – -0.68) and low mutual dependence between K1 and k3 (median R: 0.06, IQR: -0.38 – 0.43), 
between k2 and k3 (median R: 0.36, IQR: -0.13 – 0.68), between k2 and Vb (median R: -0.60, IQR: 
-0.70 – -0.54) and between k3 and Vb (median R: 0.34, IQR: 0.03 – 0.66). 
 
Discussion 
When comparing tumor regions with stepwise decreasing MRglc, there is decreasing 
phosphorylation rate (k3) but increasing fractional blood volume (Vb). This cannot be explained by 
mutual dependence of these variables in the fitting process, since the fit-correlation was low. We 
could not find a significant correlation between whole-tumor Vb and k3 between lesions. Glucose 
phosphorylation rate therefore is not correlated with lesion blood volume fraction. Miles and Williams 
[19] have reviewed the relation between tumor vascularization and tumor metabolism. Although the 
total uptake of FDG is considered rather than k3, they show that literature on this subject is highly 
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variable. It was reported that the relationship appeared to depend on tumor type, tumor size and 
tumor grade. In this study, even in the subgroups per tumor type or the subgroup of large tumors 
there were no significant correlations between Vb and k3, see table 4. The weak correlations between 
MRglc and k3 (significant) and MRglc and Vb (not significant) might indicate that using MRglc as tumor 
segmentation variable is responsible for the within-patient inverse relation between the k3- and Vb-
trends over the segments, but the absence of between-lesion correlation between Vb and k3 suggests 
another underlying mechanism. Multiple groups reported a correlation between FDG-uptake during 
the first few minutes after injection and tumor blood-flow measured by [15O]-H2O in various tumor 
types [20;21]. Since a large Vb is mainly responsible for the tumor FDG-concentration in the (very) 
early time-frames, at which blood FDG activity concentrations are still very high, our results suggest 
that Vb (hence regional tumor perfusion) is inversely related with phosphorylation rate (k3). Our results 
suggest that the “metabolic center” of the tumor can maintain high phosphorylation rates (k3) at 
relatively low blood volume fractions (Vb). This interesting result may support the hypothesis that as 
the tumor grows, angiogenesis becomes unable to maintain an adequate blood supply, contributing to 
the uncoupling of glucose metabolism and blood flow, a theory also known as the Warburg Effect 
[22]. It should be noted that Vb as obtained with pharmacokinetic modeling may not reflect the 
complete blood fraction in the tumor. The venous blood time activity curve may have a shape very 
different from the arterial blood time activity curve as used for the compartment analysis. This could 
result in an underestimation of Vb.  
Tumor hypoxia is disadvantageous property for several cancer treatments including 
radiation therapy [23]. Numerous methods to detect or visualize hypoxia in vivo are available 
which include hypoxia specific PET tracers such as FMISO. Some suggest to employ FDG-PET 
for dose painting because of the disadvantages of hypoxia tracers, e.g., a low tumor to background 
ratio, low reproducibility, and slow clearance of these tracers in non-hypoxic regions [24]. Although 
FDG is certainly not a tracer specific for hypoxia, there is a correlation between FDG uptake and 
hypoxia in tumors [25]. More details about the metabolism of FDG can be obtained using 
dynamic PET. We have shown an inverse relation between Vb and k3, which might be indicative 
for a poorer oxygenation in the metabolic centre of the tumor, because of increased demand of 
oxygen and nutrients (higher phosphorylation), but decreased delivery (lower volume fraction of 
blood). Continuous uptake of FDG, despite a poor vasculature, is a sign of adaptation of the 
page 10 
 
 
tumor to the hypoxic conditions. The intratumoral metabolic heterogeneity suggests differences 
in the tumor microenvironment (including distribution of hypoxia), which might have an impact on 
radiation treatment planning. 
We do not believe that the high number of lesions with outlying parameters influenced our 
conclusions as we saw similar results in the subgroup of lesions in which all parameter values were 
considered biologically plausible.  
A potentially disturbing factor is image blurring, both due to partial-volume-effects and (periodic) 
movements such as breathing. However, the subgroups of lesions least influenced by both causes of 
blurring (i.e., tumor volumes at least 5 times the scanners spatial resolution) showed similar results to 
the whole-group analysis, which demonstrates the limited role of these perturbing factors on our 
results.  
 
Conclusion 
Regions of tumors with highest MRglc are characterized by high cellular uptake and 
phosphorylation rate constants with relatively low blood volume fractions. In regions with less 
metabolic activity, the blood volume fraction gradually increases and cellular uptake, washout and 
phosphorylation rate constants decrease. These results are not due to covariance of the regression 
coefficients and might be relevant for understanding tumor biology and for dose-painting in 
radiotherapy. 
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Figure legends 
Figure 1: The 2-tissue compartment FDG model with pharmacokinetic rate constants K1, k2, k3, and 
k4. The measured PET signal (shown as a gray box) is a combination of FDG in tissue and a fraction 
of blood, Vb. The influx constant, Ki, can be calculated from the other rate constants with: K1k3/(k2+k3). 
 
Figure 2: Representative example of a patient with cT3N2M0 NSCLC. The lesion’s largest diameter 
was 58 mm. A: a surface rendered image of the 3 VOIs clearly demonstrating the heterogeneity in 
FDG metabolism. B: the same lesion “opened up”. C: graph showing the activity concentration curves 
in the 4 tumor VOIs (VOIlow, VOImedium, VOIhigh and VOItumor, left axis) and in the sampled arterial 
plasma (plasma, right axis). In A and B, the edge of VOIhigh is indicated with an arrowhead, and the 
edge of VOImedium with an arrow. 
Cplasma: sampled arterial plasma activity concentration, Ctumor: tumor (VOI) activity concentration, 
NSCLC: non-small cell lung carcinoma, VOI: volume of interest. 
 
Figure 3: Differences in rate constants and blood volume fraction in different tumor VOIs.  
Friedman: Friedman’s non-parametric analysis of variance overall test. NS: not significant, 
*: significant with Wilcoxon signed rank test post-hoc analysis with Dunn’s correction applied 
(p<0.001). VOI: volume of interest. 
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Table 1: Patient characteristics (n=41). 
 Value Range 
Mean age [y] 60.8 44.7 – 77.7 
Proportion male [%] 68.3  
Median plasma glucose level [mmol·L-1] 5.2 4.2 – 8.3 
Median AA per unit body mass [MBq·kg-1] 2.7 1.6 – 5.9 
Origin of primary tumor [% of patients]:   
NSCLC 71  
CRC 24  
Breast carcinoma 5  
Origin of primary tumor [% of lesions]:   
NSCLC 82  
CRC 16  
Breast carcinoma 2  
Proposed treatment [%]:   
Induction chemotherapy 22  
First line curative chemotherapy 76  
Palliative care 2  
Differentiation [%]:   
Poor 20  
Slight 15  
Moderate 27  
Mucinous 2  
Unknown 37  
 
AA: administered activity, CRC: colorectal carcinoma, NSCLC: non-small cell lung carcinoma. 
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Table 2: VOI definitions. 
Name: Lower bound: Upper bound: 
VOIhigh BGmean +0.75 (Tmax- BGmean) Tmax 
VOImedium BGmean +0.50 (Tmax - BGmean) BGmean +0.75 (Tmax - BGmean) 
VOIlow BGmean +0.25 (Tmax - BGmean) BGmean +0.50 (Tmax - BGmean) 
VOItumor BGmean +0.25 (Tmax - BGmean) Tmax 
 
BGmean: mean background MRglc, Tmax: maximum tumor MRglc. MRglc: glucose metabolic rate. VOI: 
volume of interest. 
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Table 3: VOI characteristics. 
 VOItumor VOIhigh VOImedium VOIlow 
Median Volume * [cm3]  11.3 0.556 1.83 7.85 
(range) (1.67 – 504) (0.0795 – 8.11) (0.278 – 92.2) (1.07 – 406) 
Mean MRglc † [nmol·mL-1·min-1] 99.7 187 135 82.7 
(95%-CI) (36.4 – 274) (69.8 – 503) (50.3 – 361) (30.9 – 221) 
Median SUV [g·cm-3]  4.1 6.8 5.3 3.6 
(IQR) (2.8 – 5.5) (4.8 – 8.7) (3.7 – 6.8) (2.5 – 4.8) 
Median K1 [mL·g-1·min-1] 0.11 0.18 0.15 0.11 
(IQR) (0.077 – 0.16) (0.81 – 0.37) (0.092 – 0.23) (0.072 – 0.15) 
Median k2 [min-1] 0.44 0.99 0.55 0.40 
(IQR) (0.25 – 0.89) (0.31 – 2.9) (0.29 – 1.1) (0.22 – 0.75) 
Median k3 [min-1] 0.089 0.19 0.12 0.073 
(IQR) (0.058 – 0.12) (0.090 – 0.39) (0.070 – 0.17) (0.051 – 0.099) 
Median Vb [mL mL-1] 0.089 0.036 0.071 0.095 
(IQR) (0.057 – 0.14) (0.00063 – 0.086) (0.037 – 0.11) (0.056 – 0.15) 
 
95%-CI: 95% confidence interval; IQR: interquartile range; MRglc: mean glucose metabolic rate 
computed assuming a lumped constant of 1 and a blood volume fraction of 0; SUV: standardized 
uptake value with bodyweight correction measured 40 – 50 minutes post injection; K1-k3: rate 
constants of the 2-tissue compartment model of glucose metabolism; Vb: blood volume fraction; 
VOI: volume of interest. *one voxel equals a volume 39.75 mm3.†calculated after loge-transformation. 
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Table 4: Correlation of VOItumor parameters. 
 MRglc and K1 MRglc and k2 MRglc and k3 MRglc and Vb k3 and Vb 
All lesions (n=104) 0.286 (0.003)* -0.088 (0.372) 0.488 (<0.001)* 0.189 (0.055) 0.045 (0.652) 
NSCLC (n=85) 0.255 (0.018)* -0.114 (0.298) 0.507 (<0.001)* 0.141 (0.198) 0.102 (0.352) 
CRC (n=17) 0.235 (0.363) -0.039 (0.881) 0.363 (0.152) 0.365 (0.149) -0.159 (0.541) 
 
Correlations are obtained on a whole-lesion basis, and are expressed as Spearman’s ρ with statistical 
significance between parentheses.*statistically significant 
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Table 5: Comparisons between tumor segments. 
 K1 k2 k3 Vb 
All lesions (n=104) 
28.1  (< 0.001) 
Follows Ttrend in 
42.3% 
26.8 (<0.001) 
Trend in 40.4% 
120.5 (<0.001) 
Trend in 78.8% 
71.6 (<0.001) 
Trend in 93.3% 
NSCLC (n=85) 
26.6 (<0.001) 
Trend in 40.0% 
16.3 (<0.001) 
Trend in 36.5% 
99.7 (<0.001) 
Trend in 77.6% 
54.5 (<0.001) 
Trend in 92.9% 
CRC (n=17) 
2.5 (0.312) 
Trend in 47.1% 
12.1 (0.002) 
Trend in 52.9% 
17.3 (<0.001) 
Trend in 82.4% 
22.2 (<0.001) 
Trend in 100% 
Plausible † (n=45) 
9.0 (0.011) 
Trend in 40.0% 
2.8 (0.247) 
Trend in 33.3% 
37.9 (<0.001) 
Trend in 68.9% 
14.4 (0.001) 
Trend in 86.7% 
Volume >14.1 cm3 
(n=40) 
25.6 (<0.001) 
Trend in 62.5% 
43.6 (<0.001) 
Trend in 65.0% 
61.4 (<0.001) 
Trend in 92.5% 
52.9 (<0.001) 
Trend in 95% 
 
Comparison between tumor segments is expressed as Friedman’s χ2 with statistical significance between 
parentheses. A trend between the segments is expressed as a percentage of lesions, for K1 – k3 this trend is 
VOIhigh>VOImedium>VOIlow, for Vb this trend is VOIhigh<VOImedium<VOIlow. † Lesions with all 12 parameters within 
the defined range of biological plausibility. 

